Evidence map›Paper›PMID 42014741›Full record

ReviewNature communications2026

Microbiota-derived metabolites as modulators of cancer immunotherapy response.

Catherine Toner-Bartelds, Iris L Mimpen, Miguel Parra-Martinez, Boudewijn M T Burgering, Emile E Voest

Abstract readReview
In one paragraph

Review in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Catherine Toner-Bartelds *Division of Molecular Oncology & Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Iris L Mimpen *Division of Molecular Oncology & Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Miguel Parra-MartinezDivision of Molecular Oncology & Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Boudewijn M T BurgeringOncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands.ORCID 0000-0002-4044-9596
Emile E VoestDivision of Molecular Oncology & Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands. e.voest@nki.nl.ORCID 0000-0001-8249-9586

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The microbiome is a key regulator of host homeostasis and immune activity, in part through the production of metabolites. These microbiota-derived metabolites can modulate both the innate and adaptive immune system, as well as directly target tumour cells, thereby regulating anti-tumour immunity and response to immunotherapy. Here, we describe the current mechanistic knowledge on how these metabolites exert their effects and outline the methodologies used to detect and assess these metabolites. Finally, we summarize microbiota-targeted therapies capable of improving microbial functionality to ultimately enhance immunotherapy responses and improve patient survival.

Indexed as

ImmunotherapyMicrobiotaNeoplasmsAdaptive ImmunityAnimalsHumansImmunity, Innate

Identifiers

PMID42014741
PMCPMC13269703

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.